Who is sponsoring NCT03731585?

NCT03731585 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT03731585?

Interventions in NCT03731585: Behavioral Intervention, Educational Intervention, Questionnaire Administration, Support Group Therapy.

What condition does NCT03731585 study?

NCT03731585 studies Non-Small Cell Lung Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8.

Is NCT03731585 still recruiting?

NCT03731585 is currently active, enrolled. Last updated 15 April 2026.

Last reviewed 2026-04-15 · How we verify

NCT03731585

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small Cell Lung Cancer Undergoing Treatment

Active, enrolled NA Last updated 15 April 2026

What this trial tests

NA trial testing Behavioral Intervention in Non-Small Cell Lung Carcinoma in 70 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

15 November 2018

Primary endpoint
30 September 2027

30 September 2027

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	70
Start date	15 November 2018
Primary completion	30 September 2027
Estimated completion	30 September 2027
Sites	1 location across United States

Drugs / interventions tested

Behavioral Intervention
Educational Intervention
Questionnaire Administration
Support Group Therapy

Conditions studied

Non-Small Cell Lung Carcinoma — all drugs for Non-Small Cell Lung Carcinoma →
Stage I Lung Cancer AJCC v8 — all drugs for Stage I Lung Cancer AJCC v8 →
Stage IA1 Lung Cancer AJCC v8 — all drugs for Stage IA1 Lung Cancer AJCC v8 →
Stage IA2 Lung Cancer AJCC v8 — all drugs for Stage IA2 Lung Cancer AJCC v8 →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, female only, with Non-Small Cell Lung Carcinoma or Stage I Lung Cancer AJCC v8. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial studies how well online psychosocial intervention works in improving social well-being and support in women who are undergoing treatment for stage I-IV non-small cell lung cancer. Psychosocial intervention techniques, such as mindfulness, compassion, and emotional processing, may improve distress and help patients manage symptoms related to non-small cell lung cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Moderators of the association between stigma and psychological and cancer-related symptoms in women with non-small cell lung cancer.
Snyder S, Kroll JL, Chen AB, Antonoff MB, et al · · 2022 · cited 9× · PMID 35726392 · DOI 10.1002/pon.5982
Pilot Randomized Controlled Trial in Women With Non-Small Cell Lung Cancer to Assess the Feasibility of Delivering Group-Based Psychosocial Care via Videoconference.
Milbury K, Kroll J, Chen A, Antonoff MB, et al · · 2021 · cited 9× · PMID 34663123 · DOI 10.1177/15347354211052520

Verify or expand the search:

Other trials of Behavioral Intervention

Trials testing the same drug.

NCT07377006 — Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer · NA · not yet recruiting
NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
NCT07282158 — Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians · NA · recruiting
NCT07202247 — Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabol · Phase 2 · recruiting
NCT06904391 — Education & Mentorship of Advanced Practice Providers to Increase Community-based Research Within the NCORP Network, COA · NA · recruiting

Other recruiting trials for Non-Small Cell Lung Carcinoma

Currently open trials in the same condition.

NCT07144280 — A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previ · Phase 3 · recruiting
NCT06222489 — Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT · Phase 2 · recruiting
NCT05358249 — Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation · Phase 1, PHASE2 · active not recruiting
NCT04585750 — The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) · Phase 1, PHASE2 · recruiting
NCT02432963 — Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy · Phase 1 · active not recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03731585 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 15 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03731585.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing